The combined company will bring together 10 well-known, billion-dollar brands.
Kimberly-Clark said on Nov. 3 that it will purchase Tylenol and Band-Aid parent company Kenvue in a $48.7 billion deal, forming an enormous consumer staples conglomerate.
The cash-and-stock deal includes Huggies-maker Kimberly-Clark paying $21.01 for each Kenvue share—a 41 percent premium from its Oct. 31 closing price. The acquisition, one of the largest on Wall Street this year, is expected to close in the second half of 2026.
The merger would bring 10 well-known, billion-dollar brands under the same umbrella, “that touch nearly half the global population through every stage of life,” according to the companies—from Kimberly-Clark’s Kleenex and Cottonelle to Kenvue’s Benadryl and Visine.
The combined company is projected to generate approximately $32 billion in annual net revenue and around $7 billion in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) in 2025, the companies said in a news release.
In addition, Kimberly-Clark and Kenvue anticipate realizing roughly $1.9 billion in cost synergies within three years of closing the deal.
It will also bolster investments in research and development, and quality and innovation capabilities.
Kenvue Chair Larry Merlo stated that the board, following a strategic review, believes the corporate combination will represent “the best path forward for our shareholders and all other stakeholders.”
Both businesses share a “commitment to developing science and technology to provide extraordinary care,” says Kimberly-Clark CEO Mike Hsu.
“Over the last several years, Kimberly-Clark has undertaken a significant transformation to pivot our portfolio to higher-growth, higher-margin businesses while rewiring our organization to work smarter and faster,” Hsu said in a statement. “We have built the foundation and this transaction is a powerful next step in our journey.”
Hsu will remain as the CEO, while three Kenvue board members will join the Kimberly-Clark board.
Kimberly-Clark shareholders will own approximately 54 percent of the newly formed company, with Kenvue shareholders owning the remaining shares.
Shares of Kimberly-Clark fell about 15 percent in premarket trading. Kenvue’s stock surged more than 17 percent.
The announcement comes as Kenvue released its third-quarter earnings report.
For the third quarter ending Sept. 28, Kenvue reported a net sales decrease of 3.5 percent and revenues totaling $3.76 billion—slightly below analysts’ estimates. The company also expects a low-single-digit drop in net and organic sales in the year ahead.
Last year, Johnson & Johnson separated itself from its consumer health unit, spinning off Kenvue.
“Now they have been able to focus on pharma innovation and medical devices, which tend to command higher growth and margins, and have avoided the cloud that the Tylenol controversy has caused KVUE,” Jay Woods, chief global strategist at Fredom Capital Markets, said in a recent note emailed to The Epoch Times.
By Andrew Moran
